Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
复制标题
DOI：
10.1056/nejmoa2029603
复制
发表时间：
2020-11-26
影响因子：
158.5
通讯作者：
Berwanger, Otavio
中科院分区：
文献类型：
--
作者：
Guimaraes, Helio P.;Lopes, Renato D.;Berwanger, Otavio
BackgroundThe effects of rivaroxaban in patients with atrial fibrillation and a bioprostic mitral valve remain uncertain.MethodsIn this randomized trial，we compared rivaroxaban（20 mg once daily）with dose-adjusted warfarin（target international normalized ratio，2.0 to 3.0）in patients with atrial fibrillation and a bioprostic mitral valve.主要结果是死亡，主要心血管事件（中风，短暂性脑缺血发作，全身性栓塞，瓣膜血栓形成，或住院治疗心力衰竭），或大出血在12个months.ResultsA共1005例患者在巴西的49个网站。利伐沙班组的主要结局事件平均发生时间为347.5天，华法林组为340.1天（差异计算为限制的平均生存时间，7.4天; 95%置信区间[CI]，-1.4至16.3; P
BackgroundThe effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain.MethodsIn this randomized trial, we compared rivaroxaban (20 mg once daily) with dose-adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve. The primary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization for heart failure), or major bleeding at 12 months.ResultsA total of 1005 patients were enrolled at 49 sites in Brazil. A primary-outcome event occurred at a mean of 347.5 days in the rivaroxaban group and 340.1 days in the warfarin group (difference calculated as restricted mean survival time, 7.4 days; 95% confidence interval [CI], -1.4 to 16.3; P